NanoFUSE Biologics

NanoFUSE Biologics is a commercial-stage regenerative medicine company focused on synthetic bone graft substitutes. Its core technology is a patented synthetic bioactive ceramic incorporating 45S5 Bioglass, which is FDA-cleared for spine and orthopedic bone healing procedures. The company has established a commercial footprint with a product portfolio available in moldable and flowable putty forms, featuring a 5-year shelf life and antimicrobial properties. NanoFUSE operates in the large and growing global bone graft substitute market, competing with both synthetic and biologic products.

Patented synthetic bioactive ceramic incorporating 45S5 Bioglass within a calcium phosphate matrix, designed for bone regeneration with antimicrobial properties and customizable delivery forms (moldable/flowable putty).

NanoFUSE competes in the crowded bone graft substitute market against major players like Medtronic, Stryker, and Zimmer Biomet, who offer extensive synthetic and biologic portfolios. It also competes with pure-play synthetic graft companies (e.g., Baxter's Actifuse, Orthofix's Trinity Evolution) and allograft processors. Differentiation is based on its bioactive glass formulation, handling characteristics, and antimicrobial claim.